was successfully added to your cart.

Your SEO optimized title page contents

Surprising Studies on Cannabinoids & Dementia- Part 1 of 5

Alzheimer’s affects one in eight people over 65, and there have been few successes at treating or preventing it. This study suggests that exciting the brain’s cannabinoid receptors may slow brain degradation and dementia.

Findings: A THC-like synthetic drug can improve memory in animals

Study: The Cannabinoid Receptor Agonist WIN 55,212-2 Regulates Glutamate Transmission in Rat Cerebral Cortex: an In Vivo and In Vitro Study (2008)

http://cercor.oxfordjournals.org/content/11/8/728.long

Location: Ohio State University

 

In 2008, the most up-to-date research on rats indicated that at least three receptors in the brain are activated by a synthetic drug similar to marijuana. These receptors are proteins within the brain’s endocannabinoid system, which is involved in memory as well as physiological processes associated with appetite, mood and pain response.

An interesting finding of this research was that receptors in this system can influence brain inflammation and the production of new neurons, or brain cells. The researchers determined that the synthetic drug WIN acts on receptors CB1 and CB2, leading to the generation of new brain cells, or neurogenesis. Those results led the scientists to speculate that the combination of lowered inflammation and neurogenesis is the reason the rats’ memory improved after treatment with WIN.

It appears that a safe, legal substance that mimics those important properties of marijuana can work on receptors in the brain to prevent memory impairments in aging.

Unfortunately, the study also found that once memory impairment is evident, the treatment is not effective. Reducing inflammation and preserving or generating neurons must occur before the memory loss is obvious.

About Michael Mayes

As Chief Executive Officer for Quantum 9, Inc., Michael has assisted in funding some of the largest commercial cannabis projects in the world. Michael has been a cannabis investor since 2009 in Colorado’s first legal for-profit cannabis market. As the co-founder and CEO of Quantum 9, Inc., Michael has spent years designing technology and collaborating with countless consultants on the forefront of the cannabis industry. Collaborating with the brightest minds and contributing to world-class organizations has been an incredibly enlightening and rewarding experience for him. Also, he has amassed a comprehensive and award-winning team engaged globally for public policy best practices through the prioritization of environmental sustainability and patient care. Michael is a member of the International Cannabinoid Research Society (ICRS), contributor to Marijuana Business Daily, quoted in the Chicago Tribune, Tampa Tribune, Yahoo Finance, Tampa Tribune, Sativa Magazine, CBC and the Daily Herald. His media appearances include several CBS and WGN appearances and international presence on BNN Commodities in Canada. On the public policy front, Michael and his team were instrumental in their work of drafting the Kentucky Medical Marijuana Bill for Senator Perry Clark. Most recently, Michael taught a class for the International Pharmaceutical Academy in Toronto, Canada. He spoke on Cannabis Pharmacology, and the effects cannabis has on the endocannabinoid system.

Leave a Reply